紫杉醇联合顺铂及长春瑞滨联合卡铂治疗老年晚期非小细胞肺癌的临床对照研究  

Clinical study of combined chemotherapy of paclitaxel plus cisplatin vinorelbine plus carboplatin for elderly advanced non-small cell lung cancer

作　　者：邱文生[1] 张彦[2] 任德玲[2] 岳麓[1] 梁军[1] 

机构地区：[1]青岛大学医学院附属医院肿瘤中心,山东青岛266003 [2]青岛市市立医院肿瘤科,山东青岛266071

出　　处：《中华肿瘤防治杂志》2006年第11期861-862,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了探讨紫杉醇联合顺铂及长春瑞滨联合卡铂方案对老年晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的疗效和毒副反应,选取初治晚期NSCLC65例,分别应用TP(紫杉醇+顺铂)、NE(长春瑞滨+卡铂)方案治疗。每例均完成2个周期化疗后评价疗效及毒副反应。结果两组患者近期有效率TP组为41·9%(13/31),NE组为41·2%(14/34),差异无统计学意义,P>0·05。中位生存期TP组8·1个月,NE组7·2个月,差异无统计学意义,P>0·05。两组毒副反应均以骨髓抑制、脱发及恶心呕吐为主,TP组恶心呕吐发生率为87·1%,NE组为73·5%,白细胞减少TP组为74·9%,NE组为85·3%。两组病例均无化疗相关死亡发生。初步研究结果提示,TP、NE联合方案是治疗老年晚期NSCLC有效且耐受性较好的方案。The objective of this study was to evaluate the efficacy and toxicity of combined chemotherapy of paclitaxel plus cisplatin vinorelbine plus carboplatin in the treatment of elderly advanced non small call lung cancer （NSCLC）. A total of 65 initially treated elderly patients with advanced NSCLC were enrolled in this study and treated by TP （paclitaxel plus cisplatin） and NE （vinorelbine plus carboplatin）. The efficacy and side effects were analyzed after two cycles of chemotherapy. Results： The overall response rates （CR＋PR） were 41.9% in the TP group and 41.1% in the NE group. No significant statistical difference was found between the two groups, P 〉 0.05. The median survival time was 8.1 months and 7.2 months respectively in the TP and NE groups. The major side effects were myelo suppression,alopecia and nausea/vomiting in the two groups. There was no chemotherapy related death in the two groups. In conclusion, the combined regimens of TP and NE are both effective and well tolerated for the elderly advanced NSCLC.

关 键 词：癌 非小细胞肺 长春瑞滨 紫杉醇 顺铂 卡铂 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]